NewsBenzingaReported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s Benzinga 2026.10.12 07:03 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on Sonoco Products, Lowers Price Target to $53 Piper Sandler Maintains Neutral on WaFd, Lowers Price Target to $31 VinFast Says Real Estate Could Cover Its EV Cash Burn Wells Fargo Maintains Overweight on Silgan Hldgs, Lowers Price Target to $52 Piper Sandler Maintains Neutral on First Finl Bankshares, Lowers Price Target to $33 $1000 Invested In Extra Space Storage 20 Years Ago Would Be Worth This Much Today
